Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-15T16:01:00.135Z Has data issue: false hasContentIssue false

Use of Novel Psychoactive Substances and Induced Psychiatric Symptoms: Outcomes From the Eivissa Project

Published online by Cambridge University Press:  23 March 2020

G. Martinotti
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
C. Montemitro
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
M. Corbo
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
F. Sarchione
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
E. Cinosi
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
A. Pasquini
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
V. Mancini
Affiliation:
Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
C. Merino del Villar
Affiliation:
Department of Psychiatry, Hospital Can Misses, Ibiza, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Polydrug abuse seems to be especially popular in Ibiza, an important market for new psychoactive substances (NPS). The misuse of psychoactive substances can lead to serious psychiatric symptoms.

Aims

To evaluate symptoms induced by NPSs and other club drugs, correlating with the main classes of drugs.

Methods

Ninety subjects (M/F 59/31) admitted in the Psychiatric Unit of Can Misses Hospital (Ibiza) referring a recent intake of substances were enrolled. The following scales were administered: TLFB (Timeline follow-back); Positive and Negative Symptoms Scale (PANSS); Symptom checklist-90 (SCL-90) ; Young Mania Rating Scale (YMRS) ; Hamilton Depression Scale (HAM-D); Hamilton Anxiety Scale (HAM-A); Modified Overt Aggression Scale (MOAS); Columbia Suicide Severity Rating Scale (C-SSRS).

Results

Polydrug abuse was reported by 67.4% of the sample; the sample was grouped by the main preferred substance in THC-, stimulants-, and depressors-users. The majority of patients reported a previous psychiatric history. Positive symptoms resulted to be higher among THC-users (P < .05). Anxiety evaluated by SCL-90 was prevalent in the group of Depressors-users (P < .05). The scores of MOAS and SCL-90 subscale for hostility/aggression resulted to be significantly (P < .01) greater in the THC-users group.

Conclusions

Some specific psychiatric symptoms are characteristic of some classes of substances and may help to identify them when a urine sample is not available. The possibility to develop psychiatric symptoms after a recent drug use is more common in two situations: (1) patients with a previous psychiatric history; (2) subjects with a history of very strong substance use.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Substance related and addictive disorders–part 1
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.